About Kritika Sarmah
Her interest in risky instruments and passion for writing made Kritika an analyst and financial journalist.
She earned her bachelor's degree in commerce and is currently pursuing the CFA program.
With her fundamental approach, she aims to help investors identify untapped investment opportunities.
Recent Articles By Kritika Sarmah
3 Tech Stocks Ripe for May Investment
With the worldwide IT spending estimated to surge over $5 trillion this year, the tech sector continues its robust expansion. So, investors might consider investing in fundamentally solid tech stocks HP Inc. (HPQ), Proto Labs (PRLB), and Hackett Group (HCKT) this month. Read more...
Should Long-Term Investors Chase GameStop (GME) or Upbound (UPBD)?
Amidst robust consumer spending, evolving customer tastes, and rapid digitalization, the specialty retail industry emerges as a hotbed for substantial growth. Now, let's turn our attention to leading specialty retail stocks, GameStop (GME) and Upbound Group (UPBD), dissecting their potential to uncover which of them is the better long-term investment...
Apple (AAPL) Quarterly Earnings Update: Buy or Wait?
Tech giant Apple (AAPL) has released its first-quarter earnings, revealing record-high services revenue. However, concerns arise from shortcomings in its wearables segments and delayed entry into the generative AI space. Let's analyze AAPL's recent performance, assess key fundamentals, and decide whether to buy or wait on the stock...
Strategies for Capitalizing on Advanced Micro Devices (AMD) Earnings Momentum
Despite an impressive first quarter earnings report, shares of Advanced Micro Devices (AMD) are in a downward spiral. Let's delve into the intricacies of AMD's current market dynamics to uncover the underlying reasons behind this unexpected turn of events...
Buy Alert: 3 Pharma Stocks Under $20 to Invest in Now
With rising medicine demand and drug shortages in the U.S., pharmaceutical stocks under $20 present lucrative opportunities for investors, promising substantial returns in a ripe market. So, I think fundamentally solid pharma stocks ACADIA Pharmaceuticals (ACAD), Amneal Pharmaceuticals (AMRX), and OptiNose (OPTN), which are currently trading under $20, could be ideal investments now. Keep reading...
Amazon (AMZN) Post-Earnings Reflection: Buy, Hold, or Sell?
Amazon (AMZN) just dropped its first quarter earnings bombshell, smashing revenue and EPS expectations and cementing its reign as a retail titan. But should you ride the wave? Let's unravel the mystery...
Coca-Cola (KO) Earnings Analysis: Is Now the Time to Buy?
Coca-Cola (KO) just announced its first-quarter results, defying expectations with solid earnings. However, let us examine its performance, segment dynamics, and financial outlook to determine whether now is the opportune moment to buy into this beverage titan...
4 Biotech Stocks to Watch Closely in May
With soaring drug demand and the recent inauguration of the National Bioeconomy Board, the biotech sector in the U.S. stands as an attractive investment opportunity. So, fundamentally strong biotech stocks Akebia Therapeutics (AKBA), Organogenesis Holdings (ORGO), Alnylam Pharmaceuticals (ALNY), and G1 Therapeutics (GTHX) might be ideal additions to one’s watchlist in May. Read more...
Mastercard (MA) Earnings Forecast: Worth a Closer Look?
Payment power Mastercard (MA) is set to announce its first-quarter earnings result on May 1st. As investors eagerly await this financial update, let us analyze the company's recent performance and strategic initiatives to gauge its potential...